SciBase letter from the CEO

STOCKHOLM, Dec. 20, 2024 /PRNewswire/ -- In 2024, SciBase has advanced its positions significantly and laid the foundation for continued growth, with a new organization in the US, success within the skin barrier segment and expansion into new markets.

Our new organization in the US is critical to our continued development and the ability to provide more patients with access to better diagnostic methods for skin cancer. Since the second half of the year, we have strengthened the organization with several people, with both broad and deep knowledge in dermatology. They also have extensive experience in commercializing new technologies, a great advantage for reaching new customers and establishing reimbursement. During the year, a new consensus report was published that supports Nevisense for the use in detection and clinical management of melanoma. The report is an important step in the commercialization of Nevisense, to obtain reimbursement and, further on to be included in the clinical guidelines for skin cancer.

We have successfully broadened our presence in the US market with more clinics in new states using Nevisense. We have added individual clinics that diagnose and treat a large number of patients with skin cancer to our target groups, which overall expands SciBase business opportunity. In areas with no reimbursement, we now offer the option of paying directly, a so-called cash-pay model. We are currently testing and evaluating this model in California, the model is proven for other technologies. In addition to establish a broader reimbursement in the US, we will initiate a so-called utility study with Nevisense in melanoma in the US to further strengthen our work to establish reimbursement.

We have also had success outside our main markets, Germany and the USA. The ambition is to expand with existing resources or with a dedicated partner in each market. The most advanced market / country is Austria with several new customers using Nevisense. During 2025 I expect new installations of Nevisense in both Italy and the United Arab Emirates. Several markets are targeted, but our primary focus remains to accelerate development in the USA and where we are primarily allocating our resources.

During the year, we have evaluated alternative ways to use Nevisense to measure the status of the skin barrier function, which is linked to a variety of skin diseases such as atopic dermatitis. Nevisense is now well established in research on the skin barrier function and there is great interest from industrial partners. We have set the strategy for the way forward and are focusing on certain indications that will be supported through studies. Initially, we will collaborate with clinics in Germany to evaluate atopic dermatitis. The planned study is expected to start in the first quarter of next year with the ultimate goal of being able to launch a new clinical application.

In 2024, we have laid the foundation for continued growth, and I look forward to the coming years with confidence. In 2025, we will continue to drive our commercialization strategy in the US with investments in our marketing organization and continue with the work to establish reimbursement and coverage thereby building for future sales growth. We continue to invest in the skin barrier segment with the goal of launching a clinical indication/application as well as improved production processes and increased capacity to meet future expected sales volumes.

I am grateful for the support from our existing shareholders as well as from our new long-term shareholders who have joined during the year. We further strengthen our owner base with new long-term shareholders through the recently announced capital raising. I look forward to including them and you on SciBase journey to broaden the use of Nevisense and thereby contribute to the early detection of skin cancer and save lives.

With best regards and happy holidays,
Pia Renaudin, CEO of SciBase

For information related to the ongoing/announced capital raise, please visit:
https://investors.scibase.se/en/mid-disclaimer/107/83  

For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se

About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

Important information

Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else.

This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Acquisition of Units in the Rights Issue should only be made on the basis of the information in the formal Prospectus published by the Company in connection with the Rights Issue and which is made available on the Company's website, www.scibase.com. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an advertisement.

This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 ("Securities Act") and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.

Forward-looking statements

This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "implies," "should," "could" and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/scibase-letter-from-the-ceo,c4085643

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/scibase-letter-from-the-ceo-302337264.html